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Angiogenesis is the formation of new blood vessels from pre-existing ones. 
This process begins with the reception by the endothelial cells of a stimulus that 
triggers the angiogenic response (Carmeliet and Jain, 2011). For that purpose, one 
endothelial cell, called tip cell, is activated and begins to migrate in direction of the 
stimulus, with the other cells of the vessel (stalk cells) following it (Tung and 
Tattersall, 2012). Several cell mechanisms are implicated at this initial step, as the 
reorganization of endothelial junctions, the migration of the tip cell by generating 
cytoskeletal protrusions called filopodia, and the proliferation of the stalk cells. The 
impairment of these processes avoid a suitable angiogenesis process (Carmeliet et al, 
1999; Vitorino et al, 2015; Serra et al, 2015).  
The activation of the endothelial cells induces an increase of the metabolism that is 
crucial, as its inhibition blocks angiogenesis (deBock et al, 2013; Verdegem et al, 
2014; Yu et al, 2017). Glycolysis is the main metabolic pathway to obtain energy by 
the synthesis of ATP in the endothelial cells (Polet and Feron, 2013), and has several 
steps that regulate the flux to allow the production of energy, and to provide the other 
metabolic pathways with intermediate metabolites of the glycolysis (deBerardinis et 
al, 2010; Eelen et al, 2015). Moreover, all the cell mechanisms that allow the growth 
of the new vessel (endothelial cell junction, migration and proliferation) need an 
efficient support of ATP to work efficiently (Van Daele et al, 1992; Moreno et al, 
2014).  
Cell metabolism is not homogenous as several enzymes can be compartmentalized 
in order to function in a more effective way (Menard et al, 2014) since the diffusion 
of ATP through the cell is not fast enough to provide energy for processes that occur 
in specific places of the cell (Jones, 1986; Hu et al, 2016). Local ATP production can 
regulate endothelial cell dynamics, the establishment of new cell-contacts, the 
movement of vesicles through cytoskeletal structures, or the reorganization of the 
cytoskeleton (Zala et al, 2013; deBock et al, 2013; Moreno et al, 2014).  
Pyruvate Kinase (PK) is a key regulatory enzyme that catalyzes the last step of the 
glycolysis. PK has three forms, L (liver), R (erythrocytes) and M (muscle). This last 
form is the one expressed in the majority of the organs in human, and has two 
isoforms M1 and M2, which differ in the regulation of their catalytic activity, as 
PKM1 is constitutively active and PKM2 can be regulated from a more inactive to a 
more active form (Yamada et al, 1990; Noguchi et al, 1986; Mazurek, 2011; 
Anastasiou et al, 2011).   
M2 isoform has a robust implication in several pathologies as cancer or inflammation 
(Christofk et al, 2008; Israelsen et al 2013). For this reason it has been investigated 
mainly in cancer cells, but there are however scarce studies in endothelial cells or 
angiogenesis (Li et al, 2014; Xu et al, 2015; Boeckel et al, 2016). As regulation of 
metabolism is crucial for angiogenesis, we decided to investigate the role of PKM2 
in this process. 
PKM2 regulation of endothelial cell processes implicated in angiogenesis 
We began analyzing which is the main isoform of PK expressed in endothelial cells 
and its role in regulating some cell processes implicated in angiogenesis. PKM2 is the 
predominant Pyruvate kinase isoform in human endothelial cells (HUVECs) as 
compared with brain and lung lysates which have predominant expression of PKM1 
or PKM2 respectively (Taniguchi et al, 2015) (Fig1A).  
 
Figure1. PKM2 is the predominant PKM isoform in endothelial cells, and is dispensable for 
proliferation.  A) Western blot analysis of HUVECs lysates. Lung and brain lysates from mouse (m) 
were used as positive controls of M1 and M2 isoforms. B, Western blot analysis of HUVECs lysates 
from M2 siRNA interfered cells. PKM2 and PKM1 expression was analyzed and β-actin was used as 
loading control. C, Proliferation curve of HUVECs along the time (D: day) n=4. D, Percentage of 
Ki67+ cells normalized to siRNA control HUVECs. n=3. ns= no significant.  
 
To analyze the role of PKM2 in endothelial cell processes we interfered HUVECs 
with a specific M2 siRNA (Fig 1B). We found that PKM2 expression is dispensable 
for the proliferation of endothelial cells, as the cell number along the days and the 
percentage of Ki67+ cells did not change in the interfered cells (Fig 1C-D).   
Next, we studied the migration capacity of HUVECs interfered for PKM2 by the 
scratch assay, obtaining that the interference reduced the percentage of wound 
closure (Fig2A-B). We demonstrated that this effect is independent from proliferation 
as the percentage of Ki67+ cells was the same in the assay, and as the wound closure 
defect was maintained in cells treated with mitomycinC, an inhibitor of cell 







Figure 2. PKM2 affects endothelial cell migration. A, Representative maximal projections of 
confocal images at the final point of scratch assay. The remaining wound is delimited with a yellow 
line. B, Quantification of percentage of wound closure compared with the initial time of the assay. 
The result was normalized to the control siRNA cells. n=7 C, Quantification of percentage of Ki67+ 
cells at the last time point of the scratch assay. The result was normalized to the control siRNA cells. 
n=3. D, Quantification of percentage of wound closed compared with the initial time of the assay, in 
cells treated with 2 mg/ml of mitomycinC.  The result was normalized to the non-treated control 




As the regulation of endothelial cell junction is a key point for angiogenesis and it 
can also be implicated in the collective migration (Hayer et al, 2016), we analyzed 
the role of PKM2 in this process. The interference of PKM2 impairs the intensity of 
Ve-cadherin, the main protein of adherens junction in HUVECs, without altering its 
protein expression. PKM2 silencing also changed junction morphology reflected by 
an increase in the proportion of discontinuous junctions, in which Ve-cadherin 
pattern is perpendicular to the membrane (Figure 3A-D). This phenotype also occurs 
in a junction-reorganization context, as is the treatment with sphingosine 1-
phosphate (S1P) (Xu et al, 2007) and it is extended to other junction proteins as 
shown by the plakoglobin staining (Figure 3E-J). Since the impairment of endothelial 
cell junctions can compromise collective migration (Hayer et al, 2016), we analyzed 
the orientation of the cells to the wound by the polarization of the Golgi apparatus 
using GM130 as a marker of that organelle (Millarte and Farhan, 2012). PKM2 
siRNA interfered cells increased the percentage of wrongly-oriented cells (Figure 3K-
L). Since the morphology of Ve-cadherin is a parameter that can affect the endothelial 
barrier function, we studied the transendothelial electrical resistance (TEER) values 
in the interfered cells, using S1P treatment as it promotes an increase of that 
parameter.  While the S1P-treated control cells incremented the TEER values after 
the stimulus, the interfered cells had a milder change leading to a worse endothelial 
barrier regulation (Figure 3M). 
 
Role of PKM2 in sprouting 
To analyze if the defects in EC processes caused by PKM2 interference had an 
implication in angiogenesis, we used first an in vitro sprouting approach, the 
microbead assay in fibrin gels (Nakatsu et al 2003) along six days, testing the 
interference at final assay day (Figure 4A-B). 
 
 
Figure 3. PKM2 regulates endothelial junction dynamics.  A, Representative maximal projections 
of confocal images of confluent HUVECs interfered for PKM2 or with a control siRNA, stained for 
Ve-cadherin. B, Quantification of Ve-cadherin mean fluorescent intensity (M.F.I), normalized to 
control siRNA. n=5. C, Representative western blot of Ve-cadherin, PKM2, and -actin from lysates 
of HUVECs interfered for PKM2.  D, Quantification of percentage of discontinuous junctions in 
PKM2-interfered HUVECs. n=3. E, Representative maximal projections of confocal images of 
confluent HUVECs treated with sphingosine 1-phosphate (S1P) 1M for 15 min, interfered for PKM2 
or with a control siRNA, stained for Ve-cadherin. F, Quantification of Ve-cadherin mean fluorescent 
intensity (M.F.I) in HUVECs treated with S1P, normalized to control siRNA. n=4. G, Quantification 
of percentage of discontinuous junctions in PKM2-interfered HUVECs treated with S1P. n=4. H, 
Representative maximal projections of confocal images of confluent HUVECs interfered for PKM2 
or with a control siRNA, stained for Ve-cadherin (green) and Plakoglobin (red) treated or not with 
S1P. I, Quantification of Plakoglobin mean fluorescent intensity (M.F.I) in HUVECs in basal 
situation, normalized to control siRNA. n=3. J, Quantification of Plakoglobin mean fluorescent 
intensity (M.F.I) in HUVECs treated with S1P, normalized to control siRNA. n=3. K, Representative 
maximal projections of confocal images of HUVECs in the scratch assay interfered for PKM2 or with 
a control siRNA, stained for Ve-cadherin (green), PKM2 (blue) and GM130 (red). L, Percentage of 
wrongly-oriented cells from experiment in K; n=3. M, Quantification of percentage of 
transendothelial electrical resistance change after the treatment with S1P in HUVECs interfered for 
PKM2. ns=no significant; * p<0,05; **p<0,01 
 
The beads covered by PKM2 siRNA HUVECshad a reduction in the number and 
length of sprouts, without defects in cell proliferation (Figure 4C-G). The number of 
filopodia, cytoskeletal structures important for sprout development (Fantin et al, 
2015) was also decreased (Figure 4H-I). Finally, we classified the morphology of 
junctions in the sprouts using a software called “patching algorithm”. This program 
allows you to distinguish patches of Ve-cadherin staining from more discontinuous 
(active) to more continuous (inactive). A correct sprouting process requires a mosaic 
of types of patches (Bentley et al, 2014). The sprouts from interfered endothelial cells 
had an accumulation of active patches that results in a significant increase in the 
proportion of them compared to control siRNA sprouts as shown by the 
active/inactive patch ratio (Figure 4J-L).  
PKM2 promotes local ATP production at EC junction  
Recently it has been reported the compartmentation of proteins to regulate specific 
processes in particularly regions of the cell (Zala et al, 2013; deBock et al, 2013; 
Moreno et al, 2014). For that we investigated the subcellular localization of PKM2 
in endothelial cells. A pool of PKM2 localizes at endothelial cell junction, regions in 
which Ve-cadherin is distributed (Figure 5A). Notably we could follow PKM2 
dynamics with a GFP-PKM2 construction at the junction in response to the 
remodeling produced by S1P (Figure 5B) and observed that PKM2 is also in the same 
places than the F-actin associated to endothelial junctions (Figure 5C).  We checked 
the localization in the sprout assay, and confirmed that PKM2 is located at 
endothelial junction and also at the filopodia (Figure 5D-F). Finally we confirmed 
the membrane localization of PKM2 by subcellular fractionation of cytosol and 
membrane (Figure 5G) and that it is indeed present at the plasma membrane in a 
subfractionation of the cell membranes by density gradient (Figure 5H). 
 
 
Figure 4. PKM2 regulation of endothelial cell processes in an “in vitro” angiogenesis model. A, 
Representative western blot of HUVECs interfered for PKM2 at the final day of experiment. B, 
Representative maximal projections of confocal images of sprouts of HUVECs interfered for PKM2 
or with a control siRNA, stained for PKM2. C, Representative images of brightfield microscopy of 
spheroids of HUVECs interfered for PKM2. D, Quantification of number of sprouts in the spheroids; 
n=3. E, Quantification of sprout length normalized to control siRNA in the spheroids experiment; 
n=3. F, Representative maximal projections of confocal images of sprouts of HUVECs interfered for 
PKM2 or with a control siRNA, stained for Ki67. n=3. G, Quantification of percentage of Ki67 cells 
in the sprouts; n=3. H, Representative maximal projections of confocal images of sprouts of HUVECs 
interfered for PKM2 or with a control siRNA, stained for F-actin, showing filopodia with the asterisk 
in yellow. I, Quantification of filopodia number per tip cell normalized to control siRNA; n=5.  J, 
Representative maximal projections of confocal images of sprouts of HUVECs interfered for PKM2 
or with a control siRNA, stained for Ve-cadherin, showing patching algorithm reconstruction of Ve-
cadherin pattern from more active (red) to more inactive (blue). K, Quantification of percentage of the 




Figure5. PKM2 is located at endothelial cell junctions. A, Representative maximal projections of 
confocal images of confluent HUVECs interfered for PKM2 or with a control siRNA, stained for Ve-
cadherin (red) and PKM2 (green). B, PKM2-GFP transfected HUVECs treated with S1P 1M for 15 
min. C, Representative maximal projections of confocal images of confluent HUVECs interfered for 
PKM2 or with a control siRNA, stained for F-actin (red) and PKM2 (green) in basal situation or in 
S1P-treated cells. D, Representative maximal projections of confocal images of sprouts of HUVECs 
interfered for PKM2 or with a control siRNA, stained for Ve-cadherin (red) and PKM2 (green). E, 
Magnification of D, showing PKM2 and Ve-cadherin colocalization at junctions. F, Magnification of 
D, showing colocalization of PKM2 and F-actin at the filopodia. G, Representative western blot of 
HUVECs subfractionation of cytosol (cyt) and membrane (mem). WL is whole lysate. Expression of 
PKM2, Ve-cadherin as membrane marker, and Rho-GDI as cytosol marker are shown in HUVECs 
treated or not with S1P 1M for 15 min. H, Membrane subfractionation in optiprep gradient showing 
the expression of PKM2, gamma-catenin as plasma membrane marker, EEA1 as endosome marker, 
and GM130 as Golgi marker in cells treated with S1P or left untreated.  
 
As PKM2 is an enzyme that produces ATP directly, we hypothesize that the observed 
defects could be produced by a defect in this function at endothelial junctions. First 
we studied the metabolic state of the interfered cells. The ECAR values that reflect 
the glycolysis flux were reduced, but not the oxygen consumption, reflecting that the 
function of the mitochondria remained intact (Figure 6A-C). We analyzed in turn 
the ATP levels and pyruvate kinase activity in cell fractions obtained by saponin 
permeabilization, separating cytosol and cytoskeleton-membrane. We tested the 
different expression of Ve-cadherin and β-actin in those fractions, and found that 
PKM2 is located at both fractions by Western blot (Figure 6D) and that it is 
distributed along cytoskeleton after the permeabilization by immunofluorescence 
(Figure 6E). We discovered that ATP was reduced in the total cell and in both 
fractions, and the pyruvate kinase activity was decreased in cytosol and in the 
cytoskeleton-membrane of PKM2 silenced cells, and that the activtity was higher in 
the cytoskeleton-membrane  fraction (Figure 6F-I). This fact could explain that the 
proliferation was not affected by PKM2, as the lower activity in the cytosol may 
allow the accumulation of intermediate metabolites of the glycolysis that provide 
substrates for the proliferation, while in the other locations PKM2 is more active, 





Figure 6. PKM2 regulates ATP local production from glycolysis at endothelial junctions. A, 
Normalized ECAR (extracellular acidification ratio), in PKM2 interfered HUVECs. n=4. B, 
Normalized basal oxygen consumption (OCR) in PKM2-interfered HUVECs. n=4. C, Normalized 
maximal oxygen consumption (OCR) in PKM2-interfered HUVECs. n=4. D, Representative western 
blot of saponin permeabilization in HUVECs. Control situation (-/-) is only PBS. E, Representative 
maximal projections of confocal images of saponin permeabilized HUVECs stained for F-actin (red) 
and PKM2 (green). F-H, Normalized ATP quantification in saponin-permeabilized interfered 
HUVECs, in total cell (F), cytosol fraction (G) and in cytoskeletal-membrane fraction (H) n=4.  I, 
Normalized PK activity per g of protein quantification in cytosol and cytoskeletal-membrane 
fractions. n=4. J, Representative maximal projections of confocal images of HUVECs expressing Go-
aTeam1. K, Normalized OFP/GFP fluorescent intensity of Go-aTeam1 in HUVECs interfered for 
PKM2, along the time. n=4. L, OFP/GFP ratio decrease in HUVECs treated with 2mM of 2-
Deoxyglucose for 15 min. n=3. ns= no significant; * p<0,05; ** p<0,01; ***p<0,001; **** p<0,0001.  
 
Indeed we also found that the levels of ATP were lower by the observation of a 
fluorescence construction, GO-aTeam1, which allows the quantification of ATP at 
subcellular levels (Nakano et al, 2011) (Figure 6J-K). Finally we compared the 
decrease in the ratio of the GO-aTeam1 by PKM2 interference, with the produced by 
the inhibition of glycolysis with 2-deoxyglucose (2-DG), a general inhibitor of this 
metabolic pathway (Chuang et al, 2015). The reduction on the dye ratio produced in 
PKM2-interfered cells was significantly lower than in control cells, reflecting that this 
difference were caused by PKM2 and it was similar to the variation obtained in the 




Figure 7. PKM2 inhibition reproduces the effects of PKM2 interference. A, HUVEC number along 
the days in Shikonin (SK) (2M) treated cells. n=4. B, Normalized wound closure in cells treated with 
SK.n=3. C, Representative maximal projections of confocal images of HUVECs stained with Ve-
cadherin, treated with SK, and with or without S1P. D and E, Quantification of percentage of 
discontinuous junctions from experiments in C. n=3. F, Representative images of brightfield 
microscopy of spheroids of HUVECs treated with Shikonin. G, Normalized sprout number of 
spheroid from F. n=3.  H, Sprout length of spheroids treated with SK. n=3. ns=no significant; * 
p<0,05; ** p<0,01; ***p<0,001 
 
 
To test the hypothesis that the reduction of local ATP by the decrease in PKM2 
activity is the responsible of the phenotype, we used shikonin, an specific inhibitor of 
PKM2 isoform (Chen et al, 2011). We found that the migration and the endothelial 
cell dynamics, but not the proliferation, were affected with the treatment, both in cells 
in culture and also in the spheroid sprouting assay, so the phenotype observed by the 
interference approach was reproduced (Figure 7A-H). 
PKM2 regulates angiogenesis in vivo 
Finally we analyzed the impact of reducing PKM2 in the vascular development in 
the postnatal mouse retina, by the intravitreal injection of siRNA, which decreased 
the expression of PKM2 (Figure 8A). We found that the radial vascular growth was 
reduced, and also the filopodia number in the front (Figures 8B-D). However 
vascular density was no different (Figure 8E) so we quantified the number of 
endothelial cells by staining of ERG, a specific nuclear protein of the  endothelium, 
obtaining that the number of positive cells for this marker was the same in the PKM2-
silenced retinas (Figure 8F), suggesting that proliferation was no compromised. EC 
junction pattern was also impaired as the ratio between active and inactive patches 
of Ve-cadherin was increased in the PKM2 siRNA retinas (Figures 8G-I). 
We injected shikonin to test if the inhibition of PKM2 activity could mimic the 
phenotype of the interference as in the in vitro assays. Thus, radial expansion of 
retinal vessels was reduced in the treated retinas (Figure 8J) just like filopodia number 
(Figure 8K). Vascular density and ERG+ cells per area were not different from the 
DMSO-treated retinas (Figures 8L-M). Finally, EC junction pattern was also 
compromised (Figures 8N-P). 
 
 
Figure 8. PKM2 activity regulates angiogenesis in vivo. A, Representative Western blot of PKM2 
interference in retina. B, Representative maximal projection of confocal images of retina vessels 
stained for isolectin B4. C, Normalized vessel radial growth quantification in PKM2-interfered retinas. 
n=8. D, Filopodia number per 100 m of tip cell perimeter in PKM2-interfered retinas; n=4.  E, 
Normalized vascular density quantification in PKM2-interfered retinas; n=4. F, Normalized ERG+ 
cells per area in PKM2-interfered retinas; n=4. G, Patching algorithm junction reconstruction of Ve-
cadherin staining in PKM2-interfered retinas. n=8. H, Quantification of different types of patches of 
Ve-cadherin in PKM2-interfered retinas. n=8. I, Quantification of active/inactive patches in PKM2-
interfered retinas. n=8. J, Normalized vessel radial growth quantification in Shikonin (40 M) treated 
retinas. n=8. K, Filopodia number quantification in Shikonin (40 M) treated retinas. n=3. L, 
Normalized vascular density in Shikonin (40 M) treated retinas. n=6. M, Normalized ERG+ cells 
per area in Shikonin (40 M)-treated retinas. n=6. N, Patching algorithm junction reconstruction of 
Ve-cadherin staining in Shikonin (40 M) treated retinas. O, Quantification of different kind of 
patches of Ve-cadherin in Shikonin (40 M)-treated retinas. n=4. P, Quantification of active/inactive 
patches in Shikonin (40 M) treated retinas. n=4. ns=not significant; * p<0,05; **p<0,01 
 
In conclusion, we have described the role of PKM2 in angiogenesis, regulating 
endothelial junctions and cytoskeletal dynamics by local ATP production. Due to the 
importance of PKM2 in pathologies such as cancer, we provided novel features to 
take in account to develop new PKM2-based strategies for improvement of treatment 



























1. The pyruvate kinase isoform that is more expressed in human endothelial cells is 
PKM2. 
 
2. The endothelial proliferation is not influenced by the expression levels neither by 
the activity of PKM2. 
 
3. PKM2 regulates the endothelial cells dynamics affecting collective cell migration 
and the sprouting, “in vitro”. 
 
4. The pyruvate kinase activity is higher in cytoskeletal and membranal subcellular 
compartments than in cytosol. 
 
5. PKM2 dependent ATP production is also compartmentalized at junctional and 
cytoskeletal associated regions contributing to the regulation of the functions that 
occur at that places.   
 
6. The treatment with a specific inhibitor of the M2 pyruvate kinase isoform 
demonstrates that the activity of PKM2 is necessary for the reorganization of 
endothelial junctions, migration, and sprouting, “in vitro”. 
 
7.  PKM2 regulates the junction dynamics and the cytoskeletal protrusions in 
endothelial cells affecting “in vivo” vascular development in physiological 
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